A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients with Systolic Heart Failure

Administered By

Contributors

Start/End

  • September 5, 2017 - July 21, 2020